CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023 07:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
Cormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023
March 21, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Regulatory and Manufacturing Updates
March 02, 2023 16:05 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
January 17, 2023 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections
December 06, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 07:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
November 07, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10
November 02, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
October 20, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
September 07, 2022 08:30 ET
|
CorMedix, Inc.
BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention...